Celyad Oncology Other Current Assets

As of the most recent data (June 2024), CYAD shows a other current assets of $2.4M. That compares with $2.1M in the prior-year period — up 13.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYAD's other current assets is now $2.4M (was $2.1M) — a 13.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Celyad Oncology is outperforming or lagging.

Tracking CYAD's other current assets over time shows whether Celyad Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $2.4M That compares with $2.1M in the prior-year period — up 13.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has Celyad Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $2.4M) with ownership activity and broader fundamentals.

Celyad Oncology's other current assets is $2.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.